PeptidePedia The community reference

Contributions of AppendixAlva

User contributions·21 logged edits·page 1 of 1

Contributions by AppendixAlva, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,566 edits includes activity predating the current log.

  1. 08:50, 21 Jun 2026 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 add the discontinuation rate attributable to this effect
  2. 09:12, 20 Jun 2026 (diff | hist) ChinaPeptides 14,979 ±0 m label the reception tally as weak, self-selected evidence at this point of use
  3. 22:36, 14 Jun 2026 (diff | hist) Custom peptide synthesis 4,773 ±0 add the cross-link to the temperature-excursion article
  4. 09:17, 10 Jun 2026 (diff | hist) SURMOUNT trial programme 5,021 ±0 m add the year of publication to each trial in the list
  5. 09:06, 22 Apr 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 rm the claim that the position has changed; no source supports it
  6. 16:37, 10 Apr 2026 (diff | hist) Triple agonist 4,269 ±0 m correct the dose ladder — the maintenance dose is not the maximum dose
  7. 09:13, 9 Apr 2026 (diff | hist) Contraindications of incretin therapy 4,993 ±0 correct the percentage — source reports it per patient-year
  8. 01:12, 1 Apr 2026 (diff | hist) Syringe dead space 20,859 ±0 correct the unit conversion — U-100 not U-40
  9. 23:49, 12 Feb 2026 (diff | hist) STEP trial programme 5,534 ±0 split overlong sentence
  10. 04:46, 25 Jan 2026 (diff | hist) SURPASS trial programme 5,078 ±0 ce, tighten prose
  11. 21:32, 3 Nov 2025 (diff | hist) Tianjin Finder Chemical 13,749 ±0 m add the lead time for catalogue lines, as reported
  12. 08:37, 14 Oct 2025 (diff | hist) Talk:Trial data comparison 1,096 +194 /* Head-to-head filter: is the flag applied consistently? */ reply
  13. 07:38, 30 Sep 2025 (diff | hist) Peptide stability table 5,688 ±0 the calculator rounded before dividing; corrected
  14. 14:26, 12 Jul 2025 (diff | hist) Placebo-adjusted effect 4,581 ±0 m space between number and unit per PP:MOS
  15. 16:22, 4 May 2025 (diff | hist) FLOW trial 3,481 ±0 m add the PMID
  16. 10:10, 21 Apr 2025 (diff | hist) Counterfeit peptide 4,002 +26 m clarify that a signature on a certificate is a release, not a verification
  17. 23:54, 18 Apr 2025 (diff | hist) SURPASS trial programme 4,474 +516 expand §The head-to-head comparison
  18. 00:54, 5 Dec 2024 (diff | hist) Placebo-adjusted effect 2,853 ±0 the article attributed a finding to the wrong trial in the programme
  19. 01:47, 21 Nov 2024 (diff | hist) Retatrutide 4,481 +404 rm the equipotency claim — the cited paper does not make it
  20. 00:15, 23 Oct 2024 (diff | hist) Cold-chain freight 1,900 ±0 m correct the freezer temperature range given for long-term storage
  21. 16:49, 21 Sep 2024 (diff | hist) Intention-to-treat analysis 2,660 +493 label the extension study as an extension study in the table